PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.43%
Both companies show declining cash positions (-3.43% vs AGEN's -13.11%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-3.43%
Below half of AGEN's -16.58%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
967.92%
Other current assets growth < half of AGEN's -27.03%. David Dodd sees a leaner approach to short-term items.
-3.05%
Below half of AGEN's -16.99%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
0.98%
0.5-0.75x AGEN's 1.41%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of AGEN's 109.50%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
0.98%
Below half of AGEN's 2.75%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Below half of AGEN's -7.09%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-106.99%
Less than half of AGEN's 13.57%. David Dodd sees fewer expansions in other current obligations.
16.37%
Above 1.5x AGEN's 6.90%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of AGEN's -6.83%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
2.58%
Less than half of AGEN's -1.20%. David Dodd sees far fewer liability expansions relative to competitor.
3.85%
50-75% of AGEN's 7.55%. Bruce Berkowitz notes minimal new equity relative to competitor.
-5.06%
1.25-1.5x AGEN's -3.88%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.22%
Below half AGEN's -59.21%. Michael Burry sees potential underperformance in building shareholder capital.
-2.92%
Below half AGEN's -7.09%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-5.00%
Above 1.5x AGEN's -0.46%. Michael Burry sees a major jump. Investigate leverage rationale.
3.39%
Less than half of AGEN's 27.52%. David Dodd sees better deleveraging or stronger cash buildup than competitor.